---
actionable_items:
- action: technically
  category: investigation
  full_context: 'opportunity to technically '
  priority: medium
companies:
- category: unknown
  confidence: medium
  context: Welcome everyone to the AI and Business Podcast. I'm Matthew Damello, editorial
    director here at
  name: Business Podcast
  position: 31
- category: unknown
  confidence: medium
  context: come everyone to the AI and Business Podcast. I'm Matthew Damello, editorial
    director here at Emerge AI Research. T
  name: Matthew Damello
  position: 53
- category: unknown
  confidence: medium
  context: . I'm Matthew Damello, editorial director here at Emerge AI Research. Today's
    guest is Patricio Lerosa, head of end-to
  name: Emerge AI Research
  position: 97
- category: unknown
  confidence: medium
  context: ctor here at Emerge AI Research. Today's guest is Patricio Lerosa, head
    of end-to-end decision science at seed prod
  name: Patricio Lerosa
  position: 134
- category: unknown
  confidence: medium
  context: decision science at seed production innovation in Bayer Crop Science. With
    over 20 years of experience developing AI a
  name: Bayer Crop Science
  position: 220
- category: unknown
  confidence: medium
  context: t helped us create a proper power for that study. Now I can give you an
    example in, in areas such as the,
  name: Now I
  position: 5968
- category: unknown
  confidence: medium
  context: als that couldn't be more dissimilar in this way. If I can point out, you
    know, the protein being able t
  name: If I
  position: 11860
- category: unknown
  confidence: medium
  context: a patient journey is going to be very different. But I've had a number
    of healthcare professionals come
  name: But I
  position: 13242
- category: unknown
  confidence: medium
  context: a span of ancient right, commitment to the cost. So I think a gamification,
    which is being used in soci
  name: So I
  position: 15404
- category: unknown
  confidence: medium
  context: ble, but that also depends on the clinical trial. And I'm also a guy who
    makes podcasts. So yeah, so I'm
  name: And I
  position: 19176
- category: unknown
  confidence: medium
  context: the folks who might not be, as I might call them, James Bond villains in
    different fraud workflows, like folks
  name: James Bond
  position: 20545
- category: unknown
  confidence: medium
  context: right? And is used a lot in observational study. Once I have collected
    the information, I want to stratif
  name: Once I
  position: 21293
- category: ai_research
  confidence: high
  context: The host's organization, which focuses on AI research and likely publishes
    content related to AI in business.
  name: Emerge AI Research
  source: llm_enhanced
- category: ai_application
  confidence: high
  context: Patricio Lerosa's employer, which uses AI/ML in seed production innovation
    and applies decision science across agriculture and life sciences.
  name: Bayer Crop Science
  source: llm_enhanced
- category: ai_technology
  confidence: high
  context: Mentioned as a key technology driving development and enabling language
    to talk to each other in healthcare and life sciences.
  name: LLMs (Large Language Models)
  source: llm_enhanced
- category: ai_technology
  confidence: high
  context: The overarching subject, used broadly for predicting patient outcomes,
    tailoring solutions, and optimizing clinical trials.
  name: AI
  source: llm_enhanced
- category: ai_technology
  confidence: medium
  context: Mentioned as an AI technology being used upstream in drug development to
    manipulate and authenticate proteins.
  name: Digital Twins
  source: llm_enhanced
- category: ai_technology
  confidence: high
  context: Used to provide targeted explanations to patients during recruitment.
  name: NLP (Natural Language Processing)
  source: llm_enhanced
- category: ai_technology
  confidence: high
  context: Suggested use case for identifying patients who are more empathic and responsible
    regarding trial participation.
  name: Sentiment Analysis (AI technique)
  source: llm_enhanced
- category: ai_technology
  confidence: high
  context: Mentioned as a mathematical technique used to identify the right sample
    size and suitable individuals for trials.
  name: Active Learning (AI technique)
  source: llm_enhanced
- category: ai_research
  confidence: high
  context: Mentioned in the context of exploring different proteins for drug development,
    implying its use in computational biology/AI drug discovery.
  name: AlphaFold
  source: llm_enhanced
date: 2025-05-13 06:00:00 +0000
duration: 33
has_transcript: false
layout: episode
llm_enhanced: true
original_url: https://traffic.libsyn.com/secure/techemergence/Business_-_5.13.25_-_Patricio_La_Rosa.mp3?dest-id=151434
processing_date: 2025-10-05 18:14:39 +0000
quotes:
- length: 47
  relevance_score: 4
  text: But today we could leverage using an LLM, right
  topics: []
- length: 252
  relevance_score: 3
  text: I think one of the biggest challenges is that as we are introducing multiple
    sensing modalities and we believe that we have identified what makes a difference,
    can that difference or that effect manifest itself as you're looking through different
    pages
  topics: []
- length: 98
  relevance_score: 3
  text: It's today, as you can see in the literature, continues to be one of the biggest
    challenges, right
  topics: []
- impact_reason: Highlights a major ethical and philosophical shift in clinical trials
    enabled by AIâ€”moving from objectification to human-centric design.
  relevance_score: 10
  source: llm_enhanced
  text: Fundamentally, it's given us the opportunity to technically make legal trials,
    not just what we will say, love experiments where the individual is just basically
    an object, but where we can now are able to technically make it more human-centric.
  topic: safety/ethics
- impact_reason: 'Identifies a major limitation/challenge in AI application: the lack
    of robustness and reproducibility of biomarkers (like fMRI signals) across different
    sites and equipment.'
  relevance_score: 10
  source: llm_enhanced
  text: Can that difference or that effect manifest itself as you're looking through
    different pages? And it's been, it's a challenge. So think about, for example,
    the identification of markers in fMRI to technically treat a mental health disease,
    right? It's today, as you can see in the literature, continues to be one of the
    biggest challenges, right? Because you don't find it, you can repeat it, you go
    to a different site, you put an fMRI and then the effect doesn't manifest itself.
  topic: limitations
- impact_reason: 'Excellent articulation of the necessary duality in modern life sciences:
    the objective STEM approach (AI for molecular engineering) versus the subjective
    humanities approach (AI for patient communication/storytelling).'
  relevance_score: 10
  source: llm_enhanced
  text: The protein being able to re-engineer, you know, what we're seeing at that
    molecular level is so ingrained in kind of the STEM fields and, you know, needs
    such an objective approach to how you're going about these changes at literally
    a microscopic level. But the ability to bring somebody along a clinical trial
    is to tell them a story... That's the humanities. That's how do we tell that story?
  topic: strategy
- impact_reason: Directly names 'active learning experimental design' as an AI technique
    applicable to optimizing complex, sequential processes like clinical trials or
    marker identification, moving beyond static analysis.
  relevance_score: 10
  source: llm_enhanced
  text: But in order for me to do this in an active dynamical manner, I can also rely
    on techniques based on AI like active learning experimental design.
  topic: Technical/Active Learning
- impact_reason: Highlights the necessary distinction between deterministic/objective
    ML (used in drug discovery) and probabilistic/generative ML (used for patient
    communication), suggesting a need for clear terminology and boundary setting.
  relevance_score: 10
  source: llm_enhanced
  text: what an AI with advanced machine learning, the same machine learning that's
    helping pick the proteins would use machine learning in a different way to generate
    text that would give recommendations to a patient. And we need different words
    for these...
  topic: Technical/Generative AI vs. Deterministic ML
- impact_reason: A key insight contrasting the deterministic nature of AI in scientific
    discovery (e.g., drug development) versus the probabilistic nature of generative
    AI.
  relevance_score: 10
  source: llm_enhanced
  text: it's especially difficult given this point of AI adoption, both in these really
    complex industries and in the culture that AI of such an objective nature, AI
    of such a deterministic nature as we see in the actual development of these drugs,
    how they are chosen on the biomarkers that runs so differently than what we see
    on the generative side with more probabilistic technologies.
  topic: technical/AI trends
- impact_reason: 'A core strategic shift: viewing trial participants not just as subjects,
    but as future customers, which improves retention and trial quality.'
  relevance_score: 10
  source: llm_enhanced
  text: So we need to treat human clinical trials also from the perspective that we're
    working with the future customers.
  topic: business/strategy
- impact_reason: Draws a powerful analogy between optimizing retail customer experience
    (speed/efficiency) and optimizing patient experience in healthcare, driven by
    ethical imperatives (Hippocratic oath).
  relevance_score: 10
  source: llm_enhanced
  text: it's uncanny how especially from the data side straight through management,
    you start to hear more and more, you know, we do need to think of these folks
    like the way our friends in retail think of their experiences because we want
    to fulfill the Hippocratic oath because we want to do what's best for the patient
    because these institutions have it really figured out to get people through a
    checkout line as fast as possible, not just in the name of the bottom line, but
    for their own good and making sure that the emergency room is clear, et cetera.
  topic: strategy/business
- impact_reason: Direct statement on the current, tangible benefit of AI in predicting
    patient outcomes, a core application in healthcare/life sciences.
  relevance_score: 9
  source: llm_enhanced
  text: AI is helping us today based on data to help us understand and predict patient
    outcomes in a more accurate manner.
  topic: predictions
- impact_reason: Crucial insight into how multi-modal data integration via AI is advancing
    biomarker discovery, which underpins targeted medicine.
  relevance_score: 9
  source: llm_enhanced
  text: The ability to incorporate different sensing modalities that are allowing
    us to basically get to the identification of biomarkers that are reliable, persisting
    time that eventually will help us develop more targeted outcomes.
  topic: technical
- impact_reason: Specific use case for LLMs in clinical trial recruitmentâ€”using unstructured
    clinical notes to find eligible patients and improve statistical power.
  relevance_score: 9
  source: llm_enhanced
  text: Today we could leverage using an LLM, right? Trying to identify from clinical,
    for example, where are those patients and what are the candidates? And better
    scrutinize them in a way that helped us create a proper power for that study.
  topic: technical
- impact_reason: Detailed explanation of the synergy between genomics (metagenomics)
    and AI to extract robust biomarkers from complex, noisy biological data.
  relevance_score: 9
  source: llm_enhanced
  text: Thanks to genetic sequencing techniques like metagenomics, we were able to
    now to basically understand and detect those bacteria by simply doing genetic
    sequencing. For women on top of that, since to the use of artificial intelligence,
    you can actually very quickly identify today, estimate the advantages and moreover,
    try to remove the effect of the different sample size to get to that bio signal
    or biomarker that you will be able to pursue that very rare disease, right?
  topic: technical
- impact_reason: 'Actionable strategic focus for R&D: prioritizing the selection and
    validation of robust, modality-agnostic biomarkers over simply applying AI to
    existing noisy data.'
  relevance_score: 9
  source: llm_enhanced
  text: We continue to invest in two things. What is the right sensing modality to
    ensure that you have a reliable, sustainable, robust biomarker that now you can
    pursue across page and regardless of the machine they're using, regardless of
    the sense of the use, so that it can manifest itself in a consistent manner.
  topic: strategy
- impact_reason: Highlights the use of Active Learning for optimizing sample size
    and control group selection, directly impacting trial efficiency and statistical
    validity.
  relevance_score: 9
  source: llm_enhanced
  text: Also helps us through more mathematical techniques of such as active learning
    to identify what is the right sample size and who are those individuals using
    medical notes assessment, of course, respecting hyper-regulations and so on, but
    we're able to identify better matches or to in order to define a test control
    group in order to pursue the objectives.
  topic: technical
- impact_reason: Proposes a specific, actionable AI/behavioral science technique (gamification
    + contextual intelligence) to solve the critical problem of patient adherence
    and data completeness in clinical trials.
  relevance_score: 9
  source: llm_enhanced
  text: I think we have an opportunity to introduce technique such as gamification,
    right? And contextual intelligence, which means is the ability for us, especially
    in studies where you're asking questions and patients need to report on a daily
    basis or now comes and seems to be, right? I think we have the opportunity to
    create tools that are able to entice them and nudge them gently and remind them
    that their participation and their support is important.
  topic: AI application/Behavioral Science
- impact_reason: Provides a powerful analogy ('last mile of analytic') for the challenge
    of ensuring adopted models or collected data actually translate into real-world
    action or insight, specifically framing engagement as the bridge.
  relevance_score: 9
  source: llm_enhanced
  text: This can be phrased in the case of model adoption as the last mile of analytic,
    but in clinical trial analysis, it's like the bridge between patient and technology
    as a way to get into your response.
  topic: Strategy/AI adoption
- impact_reason: Shows the translation of optimization/sampling techniques (used for
    identifying genetic markers) directly into optimizing patient recruitment for
    maximum statistical impact.
  relevance_score: 9
  source: llm_enhanced
  text: In the same manner, we can translate that concept in order to recruit important.
    Right. So technically, what more subject that is similar enough to this group
    in this population will make or not a difference when we are looking to understand
    whether an effect size is meaningful.
  topic: Strategy/Optimization
- impact_reason: 'A strong statement on the core ethical requirement for AI deployment:
    transparency to avoid patient/user perception of manipulation, crucial for building
    trust.'
  relevance_score: 9
  source: llm_enhanced
  text: Nobody wants to be found. Nobody wants to find that we are being basically
    used or we are being manipulated. That's not what we mean by the use of technology.
  topic: Safety/Ethics/Trust
- impact_reason: A strong statement linking ethical implementation directly to technological
    progress, which is crucial for public trust in AI.
  relevance_score: 9
  source: llm_enhanced
  text: evidently, the ethical use of technology will technically help us move forward.
  topic: safety/strategy
- impact_reason: Defines the high bar for AI-driven scientific breakthroughs to transition
    into validated, approved products (sustainability and modality independence).
  relevance_score: 9
  source: llm_enhanced
  text: That effect needs to be sustainable and independent of sites or sensitive
    modalities for us to make a difference and get approved and really have a drug
    that is effective.
  topic: strategy/predictions
- impact_reason: A powerful reminder that even the best AI/biomarker discovery requires
    human validation (clinical trials).
  relevance_score: 9
  source: llm_enhanced
  text: But at the end of the day, in order to prove or disprove whether this works
    or not, even if we found that biomarker in order to prove it, you need to work
    with people.
  topic: strategy/limitations
- impact_reason: Directly links regulatory success and future development to improving
    human interaction/customer experience in trials.
  relevance_score: 9
  source: llm_enhanced
  text: So this future of the dark development relies, right? And the proof that we
    need to provide to the regulatory agencies relies on improving our ability to
    work with the subjects, the customers.
  topic: business/strategy
- impact_reason: Specific application of NLP to improve patient communication and
    informed consent, crucial for ethical trial execution.
  relevance_score: 8
  source: llm_enhanced
  text: The use of natural language processing is allowing us to provide better explanations
    that are targeted to the knowledge of the audience, that are targeted to the patients
    that we're really welcome.
  topic: technical
- impact_reason: Connects AI's role in analyzing complex data (like microbiome research)
    to solving the challenge of identifying drivers for rare diseases.
  relevance_score: 8
  source: llm_enhanced
  text: The identification of rare disease records for us to have meaningful, meaningful
    methodologies to first detect that presence of, and the relationship of what is
    driving the disease to begin with, right? That's the whole divine marker.
  topic: predictions
- impact_reason: AI's role in improving patient retention and engagement by shifting
    recruitment messaging from purely transactional to mission-driven, leveraging
    sentiment analysis.
  relevance_score: 8
  source: llm_enhanced
  text: AI can offer an opportunity for us to tailor right recruitment campaigns that
    provides the right information to the patient where it's not just an economical
    rewarding system. AI pays you this much for you to be here. Actually, I'm able
    to communicate that your participation is meaningful as we're trying to keep it
    in the system.
  topic: business
- impact_reason: 'A novel application of sentiment analysis in clinical trials: screening
    potential participants based on alignment with the study''s mission to improve
    retention.'
  relevance_score: 8
  source: llm_enhanced
  text: AI through sentiment analysis can help us identify people who are more empathic
    with the mission and they are for more responsible.
  topic: technical
- impact_reason: This is a counter-intuitive statement suggesting AI can simulate
    or effectively deliver empathy in customer service contexts (like loan collection),
    challenging the traditional view that empathy is purely a human domain.
  relevance_score: 8
  source: llm_enhanced
  text: But for the time being, something we know that they're very good at, especially
    when we're talking to folks in financial services spaces, loan collection is actually
    empathy.
  topic: AI application/limitations
- impact_reason: Breaks down the root causes of non-adherence into three actionable
    categories (understanding, motivation/interest, clarity of instruction), which
    AI systems can be designed to diagnose and address.
  relevance_score: 8
  source: llm_enhanced
  text: What human subjects will ask our software question, what is driving the lack
    of adherence with respect to the participatory in the clinical trial? One, is
    this because I don't understand the meaning of this? Two, is it because basically
    they are not interested, I just want the economic reward, right? And third, is
    it because the information portrayal, the instructions given to me are not clear,
    right?
  topic: Behavioral Science/AI diagnosis
- impact_reason: Emphasizes the critical need to move beyond simple correlation to
    causal inference in drug development, setting a high bar for analytical rigor.
  relevance_score: 8
  source: llm_enhanced
  text: I mean, correlation will never lead us to proper drug development, right?
    And so, certification, I will say corresponds more of the type of analysis that
    we want to do to understand, hey, do similar patients that share a certain degree
    of characteristics respond or not to, to this, say, this particular treatment...
  topic: Research methodology/Causality
- impact_reason: Provides a concrete example of AI/optimization techniques being used
    in high-stakes scientific discovery (genetics) that can be translated to other
    domains like trial recruitment.
  relevance_score: 8
  source: llm_enhanced
  text: And that's a field that has been used in the area of identifying markers in
    the genetic space. It's like, so I do an experiment. I have a marker and then
    I do an experiment and try to identify whether this gene is actually causing the
    effect.
  topic: AI application/Genetics
- impact_reason: 'Offers clear strategic advice: Proactive transparency about AI''s
    role is essential for adoption and overcoming engagement challenges.'
  relevance_score: 8
  source: llm_enhanced
  text: I think the more that we are at front on how we're using technology for the
    success of the journey, the more people will come at the moment, acknowledging
    that is useful and acknowledging that we need it because we have challenges in
    engaging.
  topic: Strategy/Transparency
- impact_reason: 'Provides a business/adoption strategy: transparency drives acceptance
    and utility realization.'
  relevance_score: 8
  source: llm_enhanced
  text: the more that we are at front on how we're using technology for the success
    of the journey, the more people will come at the moment, acknowledging that is
    useful and acknowledging that we need it because we have challenges in engaging.
  topic: business/strategy
- impact_reason: References AlphaFold, acknowledging its role in discovery, but immediately
    pivots to the necessity of real-world manifestation/validation.
  relevance_score: 8
  source: llm_enhanced
  text: Without, I mean, in addition to the technology of exploring different proteins
    with AlphaFold, right? Yeah. We have to be mindful that that needs to be manifested
    somehow.
  topic: technical/AI trends
- impact_reason: 'A stark warning: poor patient engagement in trials directly jeopardizes
    future market success.'
  relevance_score: 8
  source: llm_enhanced
  text: If we don't manage to keep those people in the clinical trial, that means
    that we might know how the market afterwards. In mind.
  topic: business/strategy
- impact_reason: Reiterates the foundational need for transparency in technology use
    for overall societal success.
  relevance_score: 8
  source: llm_enhanced
  text: we need to be upfront with the technology that we use so that we can always
    be successful in this journey that we call life for all.
  topic: safety/strategy
- impact_reason: Emphasizes the critical dependency of drug development success on
    clearly defined, traceable, and statistically sound effects/biomarkers.
  relevance_score: 7
  source: llm_enhanced
  text: If we don't have an effect or we don't have a clear effect, then we don't
    have technically appropriate path to developing an important drug in this case
    or an effective drug.
  topic: strategy
- impact_reason: Briefly mentions 'digital twins' as a relevant technology spanning
    both molecular design (upstream) and clinical trial optimization (downstream).
  relevance_score: 7
  source: llm_enhanced
  text: Digital twins. It's upstream and downstream.
  topic: technical
- impact_reason: A self-reflective comment suggesting that AI is now capable of handling
    complex 'human' tasks like storytelling and empathy-driven communication, challenging
    old assumptions.
  relevance_score: 7
  source: llm_enhanced
  text: Contrary to what I learned 20 years ago when I was in the humanities, is that
    robots will never be able to do this. That's a much more complicated story.
  topic: predictions
- impact_reason: Articulates the fundamental data quality challenge in qualitative
    researchâ€”ensuring subjective responses are both honest (unbiased) and meaningful
    for analysis.
  relevance_score: 7
  source: llm_enhanced
  text: For the researcher, what we want, right, is to have data that are complete,
    no, with missing information. And we want, especially when you have qualitative
    answers from the subject, which are, I feel this way or I feel that way, you want
    them to be technically, I am biased in a way that they are meaningful, right?
  topic: Data quality/Research methodology
- impact_reason: Addresses the growing acceptance of AI agents (even complex ones)
    in sensitive interactions, setting the stage for ethical discussions around transparency.
  relevance_score: 7
  source: llm_enhanced
  text: I think the ethical considerations on the use of technology, right? I think
    today, I think you will agree with me that the development of AI agents such as
    rights, such as the note tickets, right? Or even advisors. Yep. It's coming to
    to be technically a very well accepted way of interacting.
  topic: Safety/Ethics
- impact_reason: A critical, practical takeaway regarding the deployment of complex
    AI systems in regulated fields like healthcare.
  relevance_score: 7
  source: llm_enhanced
  text: we also need a lot of education on the patient side.
  topic: business/adoption
- impact_reason: Draws a parallel between AI's success in improving customer experience
    (CX) in finance/other industries and its potential application to the patient
    journey.
  relevance_score: 6
  source: llm_enhanced
  text: AI has strong, strong use cases in making a lot of what call center experiences
    or customer experiences that were painful in a variety of industrial context much
    smoother and frictionless as they get called in other industries.
  topic: business
- impact_reason: Quantifies the financial risk associated with poor patient engagement/data
    loss in clinical trials, providing a strong business case for engagement technology.
  relevance_score: 6
  source: llm_enhanced
  text: Otherwise, the money invested in creating any recruiting campaign, technically
    it will be technically in jeopardy, right? So we actually power for the studies
    of 20% more than about because to guarantee a return.
  topic: Business/Risk management
source: Unknown Source
summary: '## Podcast Summary: Leveraging AI for Better Outcomes Across Drug Development
  - with Patricio La Rosa of Bayer


  This 33-minute episode of the AI and Business Podcast features Patricio La Rosa,
  Head of End-to-End Decision Science at Bayer Crop Science, discussing the transformative
  role of Machine Learning and AI across the drug development lifecycle, drawing parallels
  between agriculture and life sciences. The central narrative focuses on how AI is
  moving clinical trials from being purely experimental objects to more human-centered,
  efficient, and precise endeavors.


  ### 1. Focus Area

  The discussion centered on the application of **AI/ML in Drug Development and Clinical
  Trials**. Specific topics included:

  *   Predicting patient outcomes and tailoring patient engagement strategies.

  *   The critical role of reliable **biomarker identification** using multi-modal
  sensing.

  *   Optimizing clinical trial design, power calculation, and patient recruitment/retention.

  *   The intersection of **behavioral science** (gamification, contextual intelligence)
  and data science in ensuring trial adherence.


  ### 2. Key Technical Insights

  *   **Multi-Modal Sensing for Biomarkers:** AI is crucial for integrating data from
  diverse sensing modalities (e.g., genetic sequencing like metagenomics, fMRI) to
  identify robust, time-persistent biomarkers, especially for rare diseases, overcoming
  the limitations of single-source data.

  *   **LLMs in Patient Identification:** Large Language Models (LLMs) are being leveraged
  to scrutinize clinical notes and data to identify and scrutinize potential candidates
  for trials, particularly for rare conditions, improving study power.

  *   **Active Learning and Experimental Design:** Techniques like active learning,
  borrowed from genetic marker identification, are being adapted to dynamically optimize
  clinical trial recruitment by sampling the patient space step-by-step to determine
  the most informative subjects needed to prove or disprove a hypothesis economically.


  ### 3. Business/Investment Angle

  *   **Efficiency in Trial Design:** The ability to define and trace clear effects
  via robust biomarkers is key to creating "powered and precise" trials, reducing
  Type I and Type II errors, and ensuring a viable path to drug approval.

  *   **Patient Retention as ROI:** Investment in AI-driven patient engagement (using
  sentiment analysis and gamification) is critical because poor adherence jeopardizes
  the significant financial investment made in recruitment and trial setup.

  *   **The "Last Mile" of Analytics:** Behavioral science applications, like gamification,
  address the "last mile" problemâ€”ensuring the adoption and consistent execution of
  analytical insights or trial protocols by the human subjects involved.


  ### 4. Notable Companies/People

  *   **Patricio La Rosa (Bayer Crop Science):** The expert guest, bringing 20 years
  of experience from both agriculture and healthcare, emphasizing the connection between
  technical models and real-world workflows.

  *   **Matthew Damello (Emerge AI Research):** The host, guiding the conversation
  toward the intersection of technology, ethics, and human-centric design.


  ### 5. Future Implications

  The industry is moving toward highly **human-centered clinical trials** where AI
  facilitates personalized communication and engagement, fostering a partnership between
  researchers and patients. There is a strong push for **transparency and ethical
  use of AI**, ensuring patients understand how technology is being used to support
  their participation and the overall search for a cure, rather than feeling manipulated.
  The challenge remains in ensuring that complex, AI-identified biomarkers (like those
  from fMRI) are consistently reliable across different sites and equipment.


  ### 6. Target Audience

  This episode is highly valuable for **R&D professionals, Clinical Operations leaders,
  Data Scientists in Pharma/Biotech, and Healthcare Technology Investors** who need
  to understand the practical, strategic, and ethical deployment of advanced AI/ML
  within the highly regulated drug development pipeline.'
tags:
- artificial-intelligence
title: Leveraging AI for Better Outcomes Across Drug Development - with Patricio La
  Rosa of Bayer
topics:
- keywords:
  - ai
  - machine learning
  - deep learning
  - neural networks
  - llm
  - large language model
  mentions: 63
  prominence: 1.0
  topic: artificial intelligence
---

<!-- Episode automatically generated from analysis data -->
<!-- Processing completed: 2025-10-05 18:14:39 UTC -->
